Is Moderna a Bad-News Buy for 2025?

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. This helped the stock to skyrocket, reaching a high of more than $480 at its peak in 2021.Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial virus (RSV) vaccine mRESVIA -- hasn't delivered as much revenue as expected. All this has weighed on the stock, which has lost more than 90% since its peak.On top of this, at the JPMorgan Healthcare conference this week, Moderna lowered its 2025 revenue guidance, and announced more than $1 billion in cost cuts for this year and next. This follows initial spending reductions launched in 2023 to scale back the company's manufacturing infrastructure.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool